Related Experiment Video
Updated: Oct 22, 2025
09:04
Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
21.1K
Targeting the NLRP3 Inflammasome in Glaucoma
Sophie Coyle1, Mohammed Naeem Khan1, Melody Chemaly2
1Northern Ireland Centre for Stratified Medicine, Ulster University, Londonderry BT47 6SB, UK.
Biomolecules
|August 27, 2021
Summary
Glaucoma involves retinal ganglion cell damage and vision loss, with inflammation playing a key role. Targeting the NLRP3 inflammasome may offer new IOP-independent therapies to preserve vision in glaucoma patients.
Area of Science:
- Ophthalmology
- Neuroscience
- Immunology
Background:
- Glaucoma is characterized by retinal ganglion cell degeneration and optic nerve damage, leading to vision loss.
- Elevated intraocular pressure (IOP) is a major risk factor, but many patients have normal IOP, indicating other pathological mechanisms.
- Neuroinflammation, particularly involving the NLRP3 inflammasome, is increasingly recognized as a critical factor in glaucoma pathogenesis.
Purpose of the Study:
- To review glaucoma as an inflammatory disease.
- To evaluate the NLRP3 inflammasome as a potential therapeutic target for glaucoma.
- To present a hypothetical mechanism for NLRP3 inflammasome action in glaucoma.
Main Methods:
- Literature review of glaucoma pathophysiology and neuroinflammation.
- Analysis of the role of the NLRP3 inflammasome in ocular tissues and pre-clinical glaucoma models.
- Examination of IL-1β as a downstream mediator of NLRP3 inflammasome activation.
Main Results:
- The NLRP3 inflammasome is expressed in the eye and activated in glaucoma.
- NLRP3 inflammasome activation leads to IL-1β production, a pro-inflammatory cytokine elevated in glaucoma patients.
- IL-1β is implicated in driving neurotoxic inflammation, RGC death, and axon degeneration.
Conclusions:
- Glaucoma exhibits characteristics of an inflammatory disease.
- Targeting the NLRP3 inflammasome presents a promising therapeutic strategy for IOP-independent neuroprotection in glaucoma.
- Further research into the NLRP3 inflammasome pathway could lead to novel treatments for vision preservation.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
765
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
765
01:25Glaucoma: Overview
994
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
994
01:28Angle Closure Glaucoma: Treatment
896
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
896